Vicore Pharma presented promising Phase 2a trial data at the 2025 ATS Conference showing buloxibutid significantly improved lung function in idiopathic pulmonary fibrosis patients compared to existing treatments.
Boehringer Ingelheim reached 66 million patients in 2024, an 8% increase from the previous year, while investing €6.2 billion (23.2% of net sales) in research and development.
Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase III FIBRONEER-ILD trial, improving lung function in patients with progressive pulmonary fibrosis.